(P052) Human Papillomavirus in Esophageal Cancer: An Institutional Retrospective Analysis

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

There was no HPV oncogene expression in our patient cohort, which corresponds with a low-to-no prevalence of esophageal HPV infection in a population of patients in the United States. However, further studies including a larger patient cohort with pretreatment tissue analysis would still be helpful in determining the true prevalence of HPV in esophageal cancer. Patients who are treated with trimodality therapy experienced a high rate of pathologic response.

Sarah E. James, MD, PhD, Terence T. Sio, MD, Rondell P. Graham, MBBS, Michael Keeney, MD, David I. Smith, PhD, Robert C. Miller, MD; Department of Radiation Oncology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester; Department of Radiation Oncology, Mayo Clinic, Jacksonville

OBJECTIVES: Human papillomavirus (HPV) is a well-established oncogenic and prognostic factor in a number of cancers. This retrospective study aims to estimate the prevalence of HPV in esophageal cancer and investigate the potential effect of infection on treatment response.

MATERIALS AND METHODS: Esophagectomy tissue samples were obtained for 94 stage II/III esophageal cancer patients treated with trimodality therapy at our institution between 1998 and 2003. Patients with both adenocarcinoma and squamous cell histology were included. Most patients were treated with 50.4 Gy in 28 fractions with concurrent chemotherapy. Chemotherapy consisted of a platinum doublet of either cisplatin with 5-fluorouracil (5-FU) or carboplatin with paclitaxel. Subsequent to the neoadjuvant therapy course, patients underwent Ivor-Lewis esophagectomy. Fresh-frozen paraffin-embedded specimens were evaluated using quantitative polymerase chain reaction (qPCR) to measure expression of the HPV oncogenes E6 and E7 and human p16. Patient characteristics were obtained from a chart review of electronic medical records. Hematoxylin and eosin (H&E)-stained slides of fresh-frozen paraffin-embedded esophageal tumor specimens that were taken at the time of surgery were carefully reviewed and graded for treatment response. Chi-square testing was used for multivariate analysis.

RESULTS: None of the 94 samples was positive for HPV oncogene expression. Median age at time of diagnosis was 61 years. The majority of patients was male (87%). Patients had advanced disease, with most having T3N0 (13%) or T3N1 (57%) disease. A total of 89% of patients had adenocarcinoma, and 11% had squamous cell carcinoma. At the time of esophagectomy, 28 (30%) patients were found to have a complete pathologic response (pCR), 40 (43%) had a partial response, and 26 (28%) had no significant treatment response. There was no significant correlation found between pCR and age, T stage, N stage, histology, tumor location, grade, or gender. However, patients aged > 70 years were more likely to have a pCR when compared with younger counterparts (P = .07). 

CONCLUSIONS: There was no HPV oncogene expression in our patient cohort, which corresponds with a low-to-no prevalence of esophageal HPV infection in a population of patients in the United States. However, further studies including a larger patient cohort with pretreatment tissue analysis would still be helpful in determining the true prevalence of HPV in esophageal cancer. Patients who are treated with trimodality therapy experienced a high rate of pathologic response.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Related Content